Free shipping on all orders over $ 500

 About 8 results found for searched term "96-82-2" (0.116 seconds)

Cat.No.  Name Target
M3549 Orlistat FAS
Tetrahydrolipstatin; Ro-18-0647
Orlistat is an irreversible inhibitor of pancreatic and gastric lipases with IC50 of 122 ng/ml for PL from human duodenal juice.
M11098 Tenuifoliose A Others
Tenuifoliose A is a natural product from Polygala tenuifolia Willd.
M21050 Lactobionic acid Others
Galactosylgluconic acid
Lactobionic acid, an α-hydroxyacid (AHA) with antioxidation activity, is used in the development of cosmeceuticals for skin.
M40988 Tipelukast Leukotriene Receptor
KCA 757; MN 001
Tipelukast is an orally bioavailable leukotriene receptor antagonist with anti-inflammatory activity for studies related to asthma and non-alcoholic steatohepatitis (NASH).
M10407 PNU-159682 Topoisomerase
PNU159682; metabolite of nemorubicin (MMDX)
PNU-159682 is a major active metabolite of nemorubicin (MMDX) in human liver microsomes, it is a highly potent DNA topoisomerase I inhibitor with excellent cytotoxicity. PNU-159682 is a potent ADCs cytotoxin.
M30039 UK‑396082  Others
UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD).
M30056 Sergliflozin etabonate SGLT
GW-869682X
Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.
M55734 Mal-PEG4-VC-PAB-DMEA-PNU-159682  Drug-Linker Conjugates for ADC
Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.